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Abstract
Introduction: Recent studies demonstrated that circulating fibroblast growth factor (FGF)-23 was associated with risk of end
stage renal disease (ESRD) and mortality. This study aims to examine whether the predictive effect of FGF-23 is independent
from circulating levels of tumor necrosis factor receptor 1 (TNFR1), a strong predictor of ESRD in Type 2 diabetes (T2D).
Methods: We studied 380 patients with T2D who were followed for 8–12 years and were used previously to examine the
effect of TNFR1. Baseline plasma FGF-23 was measured by immunoassay.
Results: During follow-up, 48 patients (13%) developed ESRD and 83 patients (22%) died without ESRD. In a univariate
analysis, baseline circulating levels of FGF-23 and TNFR1 were significantly higher in subjects who subsequently developed
ESRD or died without ESRD than in those who remained alive. In a Cox proportional hazard model, baseline concentration of
FGF-23 was associated with increased risk of ESRD, however its effect was no longer significant after controlling for TNFR1
and other clinical characteristics (HR 1.3, p=0.15). The strong effect of circulating level of TNFR1 on risk of ESRD was not
changed by including circulating levels of FGF-23 (HR 8.7, p,0.001). In the Cox multivariate model, circulating levels of FGF-
23 remained a significant independent predictor of all-cause mortality unrelated to ESRD (HR 1.5, p,0.001).
Conclusions: We demonstrated that the effect of circulating levels of FGF-23 on the risk of ESRD is accounted for by
circulating levels of TNFR1. We confirmed that circulating levels of FGF-23 have an independent effect on all-cause mortality
in T2D.
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Introduction
Diabetic nephropathy is one of the most devastating complica-
tions of diabetes. It remains the leading cause of end-stage renal
disease (ESRD), accounting for 44% of ESRD incident cases in the
United States [1]. Type 2 diabetes (T2D) also increases risk of
mortality [2]. Increased urinary excretion of albumin has long
been considered a major determinant of diabetic nephropathy
progression. However, its value as an accurate marker of the
progression to ESRD was recently challenged [3–5]. Thus, new
markers that will better identify diabetes patients with at risk of
ESRD or mortality unrelated to ESRD are needed.
Recently, results from the Joslin Kidney Study demonstrated
that among several inflammatory markers measured, increased
concentrations of circulating Tumor Necrosis Factor Receptor
(TNFR) 1 and TNFR2 emerged as very strong predictors of
diabetic nephropathy progression to chronic kidney disease (CKD)
stage 3 or ESRD [6,7]. TNFR1 and TNFR2 are cell membrane-
bound receptors involved in apoptosis, inflammation and immune
response [8]. They are released into the extracellular space by the
action of a cleavage enzyme or by exocytosis within exosome-like
vesicles [9]. It remains unclear how circulating levels of TNFRs
impact risk of renal function decline in diabetes [6,7].
Fibroblast growth factor (FGF)-23 is an endocrine hormone
secreted by bone cells [10]. The primary physiologic actions of
FGF-23 levels are to induce phosphaturia by decreasing urinary
reabsorption in proximal tubule, to reduce active vitamin D
production and to inhibit PTH secretion [11,12]. Recent
epidemiologic studies have focused on the prognostic values of
plasma FGF-23 levels and demonstrated that the circulating level
of FGF-23 is strongly associated with higher risk of ESRD and
death in subjects with CKD [13–17]. Also, circulating levels of
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e58007FGF-23 are associated with serum levels of several inflammatory
markers in non-diabetic subjects with CKD [18,19], and with
circulating levels of TNFR1 in diabetic patients [20].
This study aims to evaluate the effect of circulating levels of
FGF-23 on risk of ESRD and mortality unrelated to ESRD in a
prospective study of T2D subjects. The question of great
importance is whether the effect of TNFR1 can account for the
effect of FGF-23, or are these two effects independent.
Materials and Methods
Study patients
The Joslin Kidney Study in T2D patients was previously
described [7]. Briefly, a random sample of Joslin Clinic patients
with T2D was recruited into the Joslin Study between 1991 and
1995. Eligibility criteria included residence in Massachusetts, T2D
diagnosed between ages 35 and 64 years, and age at examination
40 to 69 years. The study protocol and informed written consent
procedures were approved by the Joslin Diabetes Center
Institutional Review Board. Trained recruiters performed a
physical examination that included standardized measurements
of blood pressure and collected samples of urine and blood
biochemical determinations (stored at 280uC). Questionnaires
were supplemented with data from medical records and clinical
laboratory database. Of the 600 patients selected, 509 were
examined and enrolled into the study. Patients with evidence of
nephropathy unrelated to diabetes and patients in CKD stage 5
[defined as an estimated glomerular filtration rate (eGFR)
,15 ml/min per 1.73 m
2 using the Modified Diet in Renal
Disease formula] were excluded. This left 410 patients, with 85%
defining themselves as Caucasian. Three hundred eighty patients
with available plasma samples for FGF-23 measurements were
included in this study.
Assessment of albuminuria status and estimated GFR at
baseline
We determined the albumin to creatinine ratio (ACR, mg/g Cr)
using the urine sample obtained at the baseline examination. The
ACR value was converted to an albumin excretion rate (AER)
according to a previously published formula [21]. This AER was
used in the univariate and multivariate analyses.
In addition to the baseline urine, we retrieved the results of
urinalysis performed on these patients’ urine during the preceding
two-year interval from the Joslin Clinical computer database, and
converted it to an AER as previously described [21]. We
determined geometric mean AER for the preceding two-year
interval to assign an albuminuria status: normoalbuminuria
(AER,30 mg/min), microalbuminuria (AER 30–300 mg/min)
and macroalbuminuria/proteinuria (.300 mg/min).
Plasma creatinine was measured in stored baseline samples at
the University of Minnesota with the Roche enzymatic assay (Prod
No. 11775685) on a Roche/Hitachi Mod P analyzer. eGFR was
obtained from plasma concentrations of creatinine using the
IDMS-traceable Modified Diet in Renal Disease formula [5].
These measurements were performed in 2009.
Measurements of plasma markers
All plasma markers were measured in baseline specimens by
immunoassays in 2009. Circulating TNFR1 levels were deter-
mined with ELISA (Cat# DRT100, R&D Systems, Minneapolis,
MN) as previously described [7]. Plasma concentrations of C-
terminal FGF-23 were determined with ELISA (Cat# 60-6100,
Immutopics, San Clemente, CA). All measurements were
performed according to the manufacturer’s protocols.
Ascertainment of outcomes
The US Renal Data System (USRDS) maintains a roster of US
patients receiving renal replacement therapy that includes dates of
dialysis and transplantation [22]. The National Death Index (NDI)
is a comprehensive roster of deaths in the United States, and
includes date and causes of death [23]. All patients were queried
against rosters of the USRDS and the NDI covering all events up
to the end of 2004, as formerly reported [7].
Statistical Analysis
Analyses were performed in SAS software (SAS Institute, Cary,
NC, version 9.2). Differences among the three outcome groups
were tested using the chi-squared test for categorical variables, and
ANOVA with post hoc Tukey’s t-test for continuous variables.
Bonferroni correction was applied for the number of group
comparisons. Spearman rank correlation matrix was created to
evaluate the relationships among clinical variables and plasma
markers. AER and the levels of markers were transformed to their
logarithms for statistical analysis. Incidence rates of ESRD and
deaths were tested for trend across quartiles of marker distribution
using SAS macro provided by the Mayo Clinic [24,25]. To
evaluate the independent effects of markers for the prediction of
outcome, we applied Cox proportional hazard models. P,0.05
was considered significant.
Results
Baseline characteristics of the study subjects according
to outcomes
At study entry, the mean eGFR of the study group was
92631 mL/min per 1.73 m
2 and 325 subjects (86%) had
preserved renal function (eGFR $60 mL/min per 1.73 m
2).
One hundred ninety five subjects (51%) had normoalbuminuria,
114 (30%) had microalbuminuria and 71 (19%) had proteinuria.
At the end of follow-up, 249 of the 380 subjects (65%) remained
alive. ESRD had developed in 48 (13%) patients. The remaining
83 patients (22%) died without ESRD. Baseline characteristics are
summarized in Table 1 according to three outcomes: Alive,
ESRD, and Deceased. Those categorized as ESRD or Deceased
were older, had longer duration of diabetes, higher AER and
lower eGFR than those who remained Alive. The three outcome
groups did not differ significantly with regard to HbA1c.
Concentrations of two markers in baseline plasma are also
summarized in Table 1. As we previously reported, the ESRD
group showed higher baseline concentrations of TNFR1 com-
pared with the Alive group [7]. The Deceased group had levels
that, while elevated, were only half as high as the ESRD group.
Differences in plasma concentrations of FGF-23 according to
outcome groups mirrored the pattern of TNFR1. However, the
differences were weaker in case of FGF-23. Interestingly, the
plasma concentrations of FGF-23 and TNFR1 in the total study
subjects were only moderately correlated (Spearman correlation
coefficient=0.49, p,0.001).
Results of Follow-up Study
To further evaluate the effects of plasma markers on the
occurrence of ESRD and all-cause mortality, we used prospective
analysis. During 8–12 years of follow-up the cohort of 380 patients
with T2D had 3585 person-years of observation; 48 patients
developed ESRD (incidence rate; 13/1000 person-years) and 83
died due to causes unrelated to ESRD (mortality rate; 23/1000
person-years). Incidence rate of ESRD increased from 3 to 6, 10
and 46 per 1000 person-years according to increasing quartiles of
baseline FGF-23 (p,0.0001 for trend). An even more dramatic
FGF-23, TNFR1 and Progression to ESRD in Diabetes
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per 1000 person-years, p,0.0001 for trend) according to quartiles
of baseline TNFR1. Mortality rates increased from 10 to 18, 26
and 49 per 1000 person-years with increasing quartiles of baseline
FGF-23 (p,0.0001 for trend). Mortality rate increase (rates 13, 14,
26 and 53 per 1000 person-years, p,0.0001 for trend) according
to quartiles of baseline TNFR1 were very similar to that observed
for quartiles of baseline FGF-23. More detailed data about
incidence rates of ESRD and all cause mortality according to both
quartiles of baseline concentrations of FGF-23 and TNFR1 are
shown in Table 2 and in Table S1, respectively.
Risk of ESRD according to both plasma markers
Incidence rates of ESRD by quartiles of baseline plasma
concentrations of FGF-23 and TNFR1 are presented in Figure 1A.
Darker bars represent higher concentrations of FGF-23. It was
clear that although the rates increased with quartiles of FGF-23 in
univariate analysis, the risk of ESRD was restricted almost
exclusively to patients with the highest quartile of TNFR1. Among
Table 1. Baseline characteristics of subjects with T2D according to their outcome during 8–12 years of follow-up.
Baseline Characteristics Outcome P-value
Alive (n=249) ESRD (n=48) Deceased (n=83) Alive vs ESRD Alive vs Deceased
Clinical Characteristics
Male (%) 54.6 43.8 65.1 0.1672 0.0959
Age (yr) 54610 60676 0 673 . 8 610
24 7.9610
27
Duration of Diabetes (yr) 12681 8 661 6 688 . 5 610
27 5.9610
25
HbA1c (%) 8.361.7 8.961.5 8.661.6 0.0607 0.506
AER (mg/min) 20 (12–68) 657 (359–1544) 77 (20–217) ,10
228 4.8610
27
eGFR (mL/min per 1.73 m
2) 100627 60627 90630 ,10
228 0.0093
Plasma Markers
TNFR1 (pg/mL) 1188 (1006–1447) 2543 (2151–3771) 1597 (1171–2079) ,10
228 5.8610
212
FGF-23 (RU/mL) 50 (36–75) 117 (65–238) 84 (53–133) 5.6610
28 2.9610
26
Data are mean 6 SD, median (25th, 75th percentiles), or percentage. AER and plasma markers were transformed to base 10 logarithms for the statistical analyses.
Bonferroni correction for a number of groups was applied.
doi:10.1371/journal.pone.0058007.t001
Table 2. Incidence rate of ESRD in subjects with T2D stratified by quartiles of FGF-23 and TNFR1.
FGF-23 Q1 FGF-23 Q2 FGF-23 Q3 FGF-23 Q4 Total
TNFR1 Q1
Incidence rate (/1000 person-year) 00000
No of Events/No of person-years 0/439 0/396 0/203 0/45 0/1083
No of subjects 37 36 18 4 95
TNFR1 Q2
Incidence rate (/1000 person-year) 0008 . 7 1 . 0
No of Events/No of person-years 0/355 0/246 0/302 1/115 1/1019
No of subjects 31 23 29 13 96
TNFR1 Q3
Incidence rate (/1000 person-year) 4.8 0 0 10.4 3.4
No of Events/No of person-years 1/208 0/220 0/259 2/193 3/880
No of subjects 22 22 27 23 94
TNFR1 Q4
Incidence rate (/1000 person-year) 52.8 55.9 55.4 91.3 72.9
No of Events/No of person-years 2/38 6/107 9/163 27/296 44/603
No of subjects 5 14 21 55 95
Total
Incidence rate (/1000 person-year) 2.9 6.2 9.7 46.3 13.4
No of Events/No of person-years 3/1039 6/970 9/927 30/648 48/3585
No of subjects 95 95 95 95 380
Quartile cut-off values were 1049, 1302, and 1812 pg/mL for TNFR1 and 42, 60, and 96 RU/mL for FGF-23, respectively.
doi:10.1371/journal.pone.0058007.t002
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FGF-23 did not discriminate the risk of ESRD (p=0.13 for trend
according to FGF-23 quartiles). Subjects who had plasma TNFR1
concentrations in quartiles 1-2 did not develop ESRD regardless of
FGF-23 concentrations. To evaluate the effect of FGF-23 on the
development of ESRD controlling for other clinical characteristics
and plasma TNFR1, we used Cox proportional hazard models.
The results are shown in Table 3. In a univariate analyses, clinical
characteristics and both plasma markers were strongly associated
with risk of ESRD. In multivariate analyses (model #1),when
clinical characteristics were considered together with each marker,
the hazard ratio (HR) for TNFR1 and FGF-23 declined
significantly but still remained associated with risk of ESRD (HR
8.4, 95% C.I. 3.1–22.6 for one quartile increase of TNFR1 and
HR 1.6, 95% C.I. 1.2–2.1 for one quartile increase of FGF-23). In
model #2 when both markers were considered together with
clinical characteristics, only the HR for TNFR1 was significant
(HR 6.9, 95% C.I. 2.5–19.0 for one quartile increase). The effect
of FGF-23 was not significant (HR 1.2, 95% C.I. 0.9–1.7 for one
quartile increase).
Mortality according to plasma markers
Rates of all-cause mortality according to quartiles of baseline
FGF-23 and TNFR1 are presented in Figure 1B. Darker bars
represent higher concentrations of FGF-23. Mortality rates clearly
increased with quartiles of FGF-23 and with quartiles of TNFR1.
The two effects were additive. To evaluate the effect of FGF-23 on
the mortality controlling for other clinical characteristics and
plasma TNFR1, we used Cox proportional hazard models. The
results are shown in Table 4. In univariate analyses only two
clinical characteristics, age and AER, were significant together
with baseline concentrations of FGF-23 and TNFR1. In multi-
variate analyses (model #1) when clinical characteristics were
considered together with each marker, the HRs for TNFR1 and
FGF-23 declined somewhat but remained strongly associated with
mortality (for one quartile increase of TNFR1, HR 1.4, 95% C.I.
1.1–1.7 and for one quartile increase of FGF-23, HR 1.6, 95%
C.I. 1.3–2.0). In model #2 when both markers were considered
together with clinical characteristics, the HR for FGF-23 was
significant (for one quartile increase of TNFR1, HR 1.1, 95% C.I.
0.8–1.5 and for one quartile increase of FGF-23, HR 1.5, 95%
C.I. 1.2–2.0).
When cardiovascular death risk (n=47) was analyzed separate-
ly, FGF-23 levels remained independent predictors in the model,
which included age, AER and TNFR1 (effect for one quartile
FGF-23 increase HR 1.4, 95% C.I. 1.0–2.0). More detailed results
are presented in Table S2.
Discussion
In our prospective study of subjects with T2D, we demonstrated
that baseline plasma concentration of FGF-23 was associated with
increased risk of ESRD. However its effect was no longer
significant after controlling for plasma concentration of TNFR1.
In other words, plasma concentration of TNFR1 accounted for the
effect of FGF-23 on risk of ESRD. However, baseline level of
FGF-23 was a significant independent predictor of all-cause as well
as cardiovascular mortality unrelated to ESRD.
Recent epidemiologic studies reported association between
plasma FGF-23 levels and clinical outcomes in patients with
CKD [13–17]. Several cross-sectional studies demonstrated that
FGF-23 levels were increased in patients with CKD [26]. Several
reports show high levels of circulating FGF-23 as a predictor of
progression to ESRD [13,14,17]. In the Chronic Renal Insuffi-
ciency Cohort Study during 3.5 years of follow-up elevated FGF-
23 was an independent risk factor for ESRD [14]. In another
follow-up study of 177 patients with non-diabetic CKD, higher
levels of C-terminal FGF-23 and intact FGF-23 were indepen-
dently associated with incident ESRD [17]. A small study of
subjects with diabetes and impaired renal function at baseline
reported that FGF-23 was a predictor of renal outcome
independent of creatinine clearance, although its 12 ESRD events
did not allow a fully adjusted Cox analysis [16].
The mechanisms are unclear as to which circulating FGF-23
may impact/be associated with impaired renal function and
contributes to progression to ESRD. In non-diabetic subjects with
impaired renal function, circulating levels of FGF-23 were
correlated with serum concentrations of several markers of
Figure 1. Incidence rate of ESRD and all-cause mortality stratified by quartiles of FGF-23 and TNFR1. Figure 1A demonstrates incidence
rate of ESRD and Figure 1B shows incidence of all cause mortality. Q1–Q4 represents quartiles 1 to 4. Quartile cut-off values were 1049, 1302, and
1812 pg/mL for TNFR1 and 42, 60, and 96 RU/mL for FGF-23, respectively. Increasing color intensity of the columns corresponds to higher
concentrations (quartiles) of FGF-23.
doi:10.1371/journal.pone.0058007.g001
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[18,19]. One study reported that elevated FGF-23 levels were
associated with TNFR1 levels in subjects with diabetic nephrop-
athy [20]. Interestingly these findings were confirmed in our study.
Table S3 shows correlations between baseline plasma levels of
FGF-23 and ACR, eGFR and plasma markers such as CRP, IL-6,
free and total TNFa, TNFR1 and TNFR2. Although these
correlations were statistically significant, they were only moderate.
The correlations between these markers and plasma level of
TNFR1, a marker that accounted for the initial effect of FGF-23
on risk of ESRD in T2D, were almost twice as strong. These
patterns of associations may indicate that both FGF-23 and
TNFR1 (TNF markers) cause progression to ESRD in the same
pathway. TNFR1 appeared to be stronger predictor, either
because it is more directly involved in progression to ESRD or
because its features as a biomarker are potentially better (i.e. better
stability over time). Another possibility is that FGF-23 is simply a
correlate of circulating level of TNFRs and is not causally related
to progression to ESRD.
The role of FGF-23 on the inflammatory pathway has not yet
been studied in depth. The effect of FGF-23 may be mediated via
expression of Klotho. Klotho is an essential cofactor of FGF-23,
expressed highly in renal tubules [27]. Higher FGF-23 levels may
be associated with low Klotho tissue expression [28,29]. Klotho
expression is down-regulated in several kidney injury models and
its over-expression attenuates renal damage in the experimental
models of kidney injury [30]. Moreno et al. reported that TNF
(TNFRs ligand) decreases Klotho expression [31]. The relation
between expression of Klotho and plasma levels of TNFRs is
unknown. On the other hand, exogenous administration of Klotho
suppressed NF-kB activation and subsequent inflammatory
cytokines production in in-vitro study [32]. A few studies
examined the clinical implication of plasma Klotho levels in
subjects with CKD, but failed to demonstrate consistent associ-
ation of Klotho levels with renal function or poor outcome [33].
Additionally, increased FGF-23 levels reduce vitamin D activation,
which has known anti- inflammatory properties [34,35]. Increase
of vitamin D levels by dietary supplement resulted in decrease of
systemic inflammatory markers such as CRP and TNFa in
subjects with T2D [36].
In contrast to the lack of independent effect of circulating FGF-
23 on progression to ESRD, our study demonstrated that FGF-23
Table 3. Univariate and multivariate Cox proportional hazard models assessing risk of ESRD adjusting for relevant baseline clinical
characteristics and plasma markers in subjects with T2D followed for 8–12 years.
Univariate analyses Multivariate analyses
Model #1 Model #2
HR* (95% CI) P-value HR* (95% CI) P-value HR* (95% CI) P-value
Clinical Characteristics
AER 4.3 (3.2–5.9) ,0.0001 2.4 (1.7–3.5) ,0.0001 2.5 (1.7–3.6) ,0.0001
eGFR 2.0 (1.7–2.3) ,0.0001 1.3 (1.1–1.6) 0.0106 1.3 (1.1–1.6) 0.01
HbA1c 1.3 (1.0–1.6) 0.027 1.3 (1.1–1.7) 0.0092 1.4 (1.1–1.7) 0.008
Plasma Markers
TNFR1 35.5 (15.0–84.0) ,0.0001 8.4 (3.1–22.6) ,0.0001 6.9 (2.5–19.0) 0.0002
FGF-23 2.8 (2.0–3.9) ,0.0001 1.6 (1.2–2.1) 0.002 1.2 (0.9–1.7) 0.15
*Effect measures are expressed as the HR for a one-quartile increase in the distribution of each covariate except for eGFR, for which it is a one-quartile decrease.
Model #1 included relevant clinical characteristics and plasma TNFR1 and FGF-23 independently.
Model #2 included relevant clinical characteristics and plasma TNFR1 and FGF-23 together.
doi:10.1371/journal.pone.0058007.t003
Table 4. Univariate and multivariate Cox proportional hazard models assessing risk of all-cause mortality adjusting for relevant
baseline clinical characteristics and plasma markers in subjects with T2D followed for 8–12 years.
Univariate analyses Multivariate analyses
Model #1 Model #2
HR* (95% CI) P-value HR* (95% CI) P-value HR* (95% CI) P-value
Clinical Characteristics
Age 1.6 (1.3–1.9) ,0.0001 1.4 (1.1–1.8) ,0.0001 1.4 (1.1–1.7) 0.0011
AER 1.4 (1.2–1.7) ,0.0001 1.2 (0.99–1.5) 0.059 1.3 (1.04–1.6) 0.0206
Plasma Markers
TNFR1 1.9 (1.5–2.4) ,0.0001 1.4 (1.1–1.8) 0.012 1.1 (0.8–1.5) 0.42
FGF-23 1.8 (1.5–2.3) ,0.0001 1.6 (1.3–2.0) ,0.0001 1.5 (1.2–2.0) 0.0005
*Effect measures are expressed as the HR for a one-quartile increase in the distribution of each covariate except for eGFR, for which it is a one-quartile decrease.
Model #1 included relevant clinical characteristics and plasma TNFR1 and FGF-23 independently.
Model #2 included relevant clinical characteristics and plasma TNFR1 and FGF-23 together.
doi:10.1371/journal.pone.0058007.t004
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including CVD deaths. Interestingly, in multivariate analyses,
FGF-23 effect accounted for an effect of circulating TNFRs on
mortality in T2D shown in our previous report [7]. The
mechanism underlying the association between FGF-23 levels
and mortality remains unclear. First, some investigators suggest
that FGF-23 levels may be a sensitive surrogate marker for the
toxicity of disturbance in phosphate and mineral metabolism in
CKD patients [15]. However, the predictive effect of FGF-23
levels is not attenuated by serum phosphate, PTH, and vitamin D
levels and FGF-23 levels are stronger predictors of mortality than
other bone-related markers [13,16]. Alternatively, FGF-23 levels
may be a surrogate marker of the severity of CKD and subsequent
increased risk of mortality. However, this scenario is also unlikely
given the observation that the association with mortality was
independent of TNFR1 levels in this study, while the association
with ESRD was not. The third possibility is that elevated FGF-23
levels may be a causal factor contributing to increased mortality.
This possibility is indirectly supported by the observation that
higher FGF-23 levels are associated with vascular calcification,
endothelial dysfunction and left ventricular hypertrophy in CKD
patients [15,37,38].
Finally, we should mention a few limitations of our study. First,
we measured only C-terminal, and not the intact form of FGF-23.
However, a recent study showed the following: both forms are
highly correlated; biologically active FGF-23 is accurately
measured by either form; and clinical associations are comparably
strong between the two [39]. Second, it is not clear how stable
plasma concentration of FGF-23 is over a period of several years.
For example, we showed that plasma concentrations of TNFR1
are very stable in patients with T1D over several years [6]. Third,
our study was conducted in mostly Caucasian subjects with T2D
so it is uncertain if our findings could be applied to Non-
Caucasians and to the subjects with T1D.
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